Back to results
US 2025/0084139 A1Published application
Compositions and methods for the treatment of cancer characterized with pcsk9 expression
AssigneeDuke University
InventorsChuan-Yuan LI, Xinjian LIU
Life of this patent
Estimating the term…
Abstract
A method for treating cancer in an individual comprises administering to the individual a therapeutically effective amount of a PCSK9 inhibitor. The method may further comprise administering to the individual at least one immune checkpoint inhibitor.
Claims16
A method for treating cancer in an individual comprising:
- administering to the individual a therapeutically effective amount of a PCSK9 inhibitor, wherein the PCSK9 inhibitor comprises an antagonistic antibody against PCSK9, wherein the antagonistic antibody is Praluent® (also known as REGN 727 [Regeneron] and SAR236553 [Sanofi]).
8-19. (canceled)
A method for treating cancer in an individual comprising:
- administering to the individual a therapeutically effective amount of a PCSK9 inhibitor, wherein the PCSK9 inhibitor comprises an antagonistic antibody against PCSK9, wherein the antagonistic antibody is Praluent® (also known as REGN 727 [Regeneron] and SAR236553 [Sanofi]);
- and administering to the individual at least one immune checkpoint inhibitor.
Dependencies are inferred from the claim text.